This brand name is authorized in Romania
The drug TELASSMO contains a combination of these active pharmaceutical ingredients (APIs):
1
Telmisartan
UNII U5SYW473RQ - TELMISARTAN
|
Telmisartan is an orally active and specific angiotensin II receptor (type AT1) antagonist. Telmisartan selectively binds the AT1 receptor. The binding is long-lasting. |
2
Amlodipine
UNII 864V2Q084H - AMLODIPINE BESYLATE
|
Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
C09DB04 | Telmisartan and amlodipine | C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09D Angiotensin II antagonists, combinations → C09DB Angiotensin II antagonists and calcium channel blockers |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W63585001, W63585002, W63585003, W63585004, W63585005, W63585006, W63585007, W63585008, W63586001, W63586002, W63586003, W63586004, W63586005, W63586006, W63586007, W63586008, W63587001, W63587002, W63587003, W63587004, W63587005, W63587006, W63587007, W63587008, W63588001, W63588002, W63588003, W63588004, W63588005, W63588006, W63588007, W63588008 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.